requires one-off treatment. antigen is human platelet antigen (HPA) 1a in 80% antigen is human platelet antigen (HPA) 1a in of cases and HPA-5b in 15%, but other antigens 80% of cases and HPA-5b in 15%, but other are also implicated. The mother’s antibodies antigens are also implicated. The mother’s cross the placenta and coat the baby’s platelets, antibodies cross the placenta and coat the with accelerated platelet clearance leading to baby’s platelets, with accelerated platelet thrombocytopenia. This may result in serious and clearance leading to thrombocytopenia. This potentially life-threatening bleeding in the foetus may result in serious and potentially or neonate. Pathogenesis is analogous to that of bleeding in the fetus or neonate. haemolytic disease of the newborn due to red cell Pathogenesis is analogous to that of haemolytic antigen-antibody incompatibility. disease of the newborn due to red cell antibody incompatibility. The aim of management of the thrombocytopenic foetus or neonate is to increase the platelet The aim of management of the count. thrombocytopenic fetus or neonate is to increase the platelet count. If foetal blood sampling reveals Instances of neonatal thrombocytopenia can thrombocytopenia, IVIg may be administered occur in situations where the mother has weekly to the mother, with or without steroids, idiopathic (autoimmune) thrombocytopenic purpura (ITP). until delivery. Recent studies using IVIg weekly from around 20 weeks gestation, without foetal If foetal blood sampling reveals blood sampling, have shown reduced foetal and thrombocytopenia, IVIg may be administered neonatal morbidity. This approach may be used weekly to the mother, with or without steroids, for current pregnancies where the condition in a until delivery. Recent studies using intravenous previous pregnancy was not associated with a immunoglobulin (IVIg) weekly from around 20 foetal death or severe haemorrhage. Testing on weeks gestation, without foetal blood sampling, maternal blood for foetal DNA or early genetic have shown reduced foetal and neonatal
antigen is human platelet antigen (HPA) 1a in 80% of cases and HPA-5b in 15%, but other antigens are also implicated. The mother’s antibodies cross the placenta and coat the baby’s platelets, with accelerated platelet clearance leading to thrombocytopenia. This may result in serious and potentially life-threatening bleeding in the foetus or neonate. Pathogenesis is analogous to that of haemolytic disease of the newborn due to red cell antigen-antibody incompatibility. The aim of management of the thrombocytopenic foetus or neonate is to increase the platelet count. If foetal blood sampling reveals thrombocytopenia, IVIg may be administered weekly to the mother, with or without steroids, until delivery. Recent studies using IVIg weekly from around 20 weeks gestation, without foetal blood sampling, have shown reduced foetal and neonatal morbidity. This approach may be used for current pregnancies where the condition in a previous pregnancy was not associated with a foetal death or severe haemorrhage. Testing on maternal blood for foetal DNA or early genetic antigen is human platelet antigen (HPA) 1a in 80% of cases and HPA-5b in 15%, but other antigens are also implicated. The mother’s antibodies cross the placenta and coat the baby’s platelets, with accelerated platelet clearance leading to thrombocytopenia. This may result in serious and potentially bleeding in the fetus or neonate. Pathogenesis is analogous to that of haemolytic disease of the newborn due to red cell incompatibility. The aim of management of the thrombocytopenic fetus or neonate is to increase the platelet count. Instances of neonatal thrombocytopenia can occur in situations where the mother has idiopathic (autoimmune) thrombocytopenic purpura (ITP). If foetal blood sampling reveals thrombocytopenia, IVIg may be administered weekly to the mother, with or without steroids, until delivery. Recent studies using intravenous immunoglobulin (IVIg) weekly from around 20 weeks gestation, without foetal blood sampling, have shown reduced foetal and neonatal requires one-off treatment. antibody
feto-maternal-neonatal-alloimmune-thrombocytopenia-fmait-nait.DOCX